(Press-News.org) Rockville, MD. (October 9, 2025) – In its mission to accelerate transformative cancer innovations and drive cures forward, the AIM-HI Accelerator Fund is pleased to announce the winners of the 2025 AIM-HI Venture Competition: ResNovas Therapeutics, co-founded by Nobel Laureate Carolyn Bertozzi, Ph.D., Michelle Arkin, Ph.D., CTO Ian Churcher, Ph.D., and CEO Gabriele Sulli, Ph.D.; and Chiara Biosciences, co-founded by National Academy of Inventors Fellow Francis Barany, Ph.D. and CEO Kirsten Flowers, MBA.
The 2025 AIM-HI Venture Competition Committee reviewed more than 80 applications from early-stage oncology companies representing 18 countries. The process was overseen by three committees—Selection, Judging, and Investment Due Diligence—each composed of world-class key opinion leaders, life sciences experts, investors, and entrepreneurs. Unlike traditional investment funds, the AIM-HI Venture Competition is building an ecosystem where every applicant receives meaningful feedback, either in writing or through a one-on-one meeting.
The AIM-HI Venture Competition is a first-of-its-kind program that provides critical funding, mentorship, and global networking opportunities to oncology startups. Both ResNovas Therapeutics and Chiara Biosciences were recognized as enterprises poised to make meaningful advances against some of the most challenging cancers. The competition highlights companies that combine strong scientific and clinical merit with the potential for transformative business and patient impact.
About the Winners
ResNovas Therapeutics is pioneering a breakthrough approach in targeted protein degradation (TPD) by leveraging novel induced-proximity mechanisms to expand the universe of druggable targets. Unlike traditional approaches, ResNovas’ breakthrough technology is built on a new class of effectors that enable the rational design of molecular glues. With this differentiated molecular glue strategy, ResNovas aims to deliver first-in-class therapies for treatment-resistant cancers, including RAS-driven tumors and beyond. Supported by industry leaders and successful serial academic founders, ResNovas is poised to drive major advancements in the TPD field.
Chiara Biosciences is creating a new category of targeted protein degraders with its proprietary CURE-PRO™ platform, which uses a “puzzle-piece” approach to overcome the size and geometry limitations of first-generation degraders. The platform enables oral delivery, CNS penetration, and the rapid discovery of novel degrader pairs. Chiara is advancing a pipeline against high-value oncogenic drivers in lung, breast, colorectal, and pancreatic cancers—diseases where new treatments could dramatically improve patient outcomes. Led by a seasoned team that has built companies acquired for up to $11 billion, Chiara is uniquely positioned to translate scientific innovation into life-changing therapies for patients.
Recognition and Leadership Perspective
The winners will be recognized at a Luncheon Award Ceremony during the 2025 NFCR Global Summit and Award Ceremonies for Cancer Research & Entrepreneurship, co-hosted by AIM-HI and the National Foundation for Cancer Research on October 24, 2025, at the National Press Club in Washington, DC.
“ResNovas and Chiara represent the type of bold innovation AIM-HI was created to empower,” said Sujuan Ba, Ph.D., Co-Founder and CEO of AIM-HI Accelerator Fund. “These innovative early-stage companies are reimagining what is possible in targeted protein degradation and drug discovery. Their breakthroughs have the potential to change the trajectory of cancer treatment worldwide. AIM-HI is proud to recognize and support both enterprises as they move their discoveries toward patients.”
“We are honored to be recognized as a winner of the 2025 AIM-HI Venture Competition. At ResNovas, our mission is to turn long-standing challenges in cancer drug discovery into opportunities to transform patient outcomes,” said Michelle Arkin, Ph.D., Co-Founder of ResNovas, who continued, “This recognition from AIM-HI validates the power of our approach and provides tremendous momentum as we advance our innovative molecular glue degrader strategy. We are deeply grateful for AIM-HI’s support and excited to continue building therapies that can bring real hope to patients facing cancers that have resisted treatment for decades.”
“To be named a winner of the 2025 AIM-HI Venture Competition is a tremendous honor for all of us at Chiara Biosciences. Our CURE-PRO platform enables us to create a new class of targeted protein degraders, and this recognition validates the potential of our science to transform outcomes for cancer patients,” said Kirsten Flowers, MBA, CEO & Co-Founder of Chiara Biosciences. “We are thankful to AIM-HI for acknowledging our vision and for the opportunity to engage with such an experienced strategic partner. This award reinforces our commitment to advancing novel therapies for the patients who need them most.”
The 2025 AIM-HI Venture Competition committees are comprised of the following persons: (listed in alphabetical order):
Anna D. Barker, Ph.D., Chief Strategy Officer, Lawrence J. Ellison Institute of Technology
Mey Boukenna, M.D., Ph.D., Vice President, Pags Group
Tom Brennan, Former Venture Partner, Arch Venture Partners
Rita Brogley, MBA, Managing Partner, Rebar Advisors, and Trinity Health Board
Webster K. Cavenee, Ph.D., Distinguished Professor Emeritus, University of California San Diego
Aleksandra Filipovic, M.D., Ph.D., Head of Oncology, PureTech Health
Pamela Garzone, Ph.D., Chief Development Officer, Anixa Biosciences
Dimitra Georganopoulou, Ph.D., General Partner, Qral Ventures
Colin Hill, Co-Founder & CEO, Aitia Bio
Raju Kucherlapati, Ph.D., Paul C. Cabot Professor of Genetics and Professor of Medicine, Harvard Medical School
Scott Lippman, M.D., Distinguished Professor of Medicine & Associate Vice Chancellor for Cancer Research, UC San Diego Health
Jimmy Lu, JD, MBA, Co-Founder and Managing Director, Eos BioInnovation
Eva Martin, M.D., Senior Director, Alliance and Asset Management, Roche Pharma Partnering
Eddie Martucci, Ph.D., Co-Founder & Chair of the Board, Akili Interactive
Bonnie Weiss McLeod, Ph.D., Of Counsel, Cooley LLP
Gregory W. Mitchell, Ph.D., Partner, Faegre Drinker Biddle & Reath LLP
Drew Pardoll, M.D., Ph.D., Director, Bloomberg- Kimmel Institute for Cancer Immunotherapy Johns Hopkins University School of Medicine
Kornelia Polyak, M.D., Ph.D., Professor of Medicine, Dana-Farber Cancer Institute
Jacob Rayyan, Ph.D., Venture Associate, Cancer Fund
Michael Salgaller, Ph.D., Supervisory Invention Development & Marketing Specialist, National Institutes of Health/National Cancer Institute
Thea Tlsty, Ph.D., Professor, Department of Pathology and Director of the Center for Translational Research in the Molecular Genetics of Cancer, UCSF
Hai Yan, Ph.D., Research Director, Institute of Molecular and Cell Biology, The Agency for Science, Technology and Research (A*Star) Singapore
Mengsu (Michael) Yang, Ph.D., Senior Vice-President (Innovation and Enterprise), City University of Hong Kong
Wai-Kwan Alfred Yung, M.D., Professor, Department of Neuro-Oncology, University of Texas, MD Anderson Cancer Center
Previous AIM-HI Venture Competition First Prize Winners Include:
2024 – HDAX Therapeutics, Nabanita Nawar, Ph.D., CEO & Co-Founder
2023 – March Biosciences, Sarah Hein, Ph.D., CEO
2022 – RiverWalk Therapeutics, Johanna Webb, President & CEO
2021 – ARDAN PHARMA, María Varela, CEO
2020 – Privo Technologies, Manijeh Goldberg, Ph.D., CEO
About the AIM-HI Accelerator Fund
The AIM-HI Accelerator Fund (AIM-HI) is a 501(c)(3) non-profit organization created in 2019 by the National Foundation for Cancer Research to provide oncology startups with the resources they need to drive innovative discoveries forward, out of the lab, to the clinics, and eventually to the people battling cancer. Our mission is to bridge the gap between research breakthroughs and clinical trials, aiming to develop innovative cancer therapies and technologies that can save patients’ lives. For more information, visit AIM-HIaccelerator.org.
About the National Foundation for Cancer Research
The National Foundation for Cancer Research (NFCR) is a 501(c)(3) nonprofit organization co-founded in 1973 by Nobel Laureate Dr. Albert Szent-Györgyi and attorney/business entrepreneur Franklin Salisbury, Sr. NFCR provides scientists in the lab with the critical seed funding they need to make game-changing discoveries in cancer detection, treatments, prevention, and ultimately, a cure for all cancers. NFCR has distinguished itself in the cancer research sector by emphasizing “high-risk, high-impact” long-term and transformative pioneering research fields often overlooked by other major funding sources. With the support of more than 5.7 million individual donors over the last 52 years, NFCR has provided more than $420 million in funding to cancer research, prevention, and public education. NFCR-supported research has led to some of the most significant life-saving discoveries that benefit patients today.
To learn more about the National Foundation for Cancer Research, visit www.NFCR.org
Media Contacts:
Ella Ye, Scientific Programs & Communications Manager, eye@AIM-HIaccelerator.org
Jonathan Larsen, CMO of NFCR, jlarsen@nfcr.org
END
AIM-HI Accelerator Fund announces winners of the 2025 Venture Competition
2025-10-09
ELSE PRESS RELEASES FROM THIS DATE:
American Society of Human Genetics to hold 2025 Annual Meeting next week in Boston
2025-10-09
Rockville, Md. - The American Society of Human Genetics (ASHG) 2025 Annual Meeting will take place October 14-18, 2025 at the Thomas M. Menino Convention & Exhibition Center in Boston, MA. Credentialed members of the press and media are eligible to request complimentary press access to attend the in-person event.
The ASHG 2025 Annual Meeting highlights cutting edge research in genetics and genomics from scientists and clinicians from around the world. Abstracts ...
Newborn genomic screening enables more lifesaving diagnoses
2025-10-09
Adding genomic sequencing to newborn blood screening would detect hundreds of additional childhood conditions, providing much earlier diagnosis and treatment, according to a new study. A baby’s genome, which stays with them for life, could also be re-examined if a health issue arises during their lifetime.
The study, led by Murdoch Children’s Research Institute (MCRI) and Victorian Clinical Genetics Services (VCGS), found genomic screening, a test that reveals a person’s entire genetic ...
AI tool offers deep insight into the immune system
2025-10-09
Researchers explore the human immune system by looking at the active components, namely the various genes and cells involved. But there is a broad range of these, and observations necessarily produce vast amounts of data. For the first time, researchers including those from the University of Tokyo built a software tool which leverages artificial intelligence to not only offer a more consistent analysis of these cells at speed but also categorizes them and aims to spot novel patterns people have not yet seen.
Our immune system is important — it’s impossible to imagine complex life existing without it. This ...
A high-performance supercapacitor made from upcycled water bottles
2025-10-09
Lots of single-use water bottles made from poly(ethylene terephthalate) (PET) end up in landfills, but there’s a growing interest in upcycling them instead. Researchers in ACS’ Energy & Fuels report on new heat-based fabrication methods to transform PET into supercapacitor electrodes and separator films for upcycled energy storage devices. In demonstrations, an all-plastic supercapacitor made from discarded water bottles outperformed a similar design that used a traditional glass fiber separator.
“PET ...
Scientists propose 4 new uses for old veggies
2025-10-09
Food waste is more than just the starting material for compost. From dried-up beet pulp to millipede-digested coconut fibers, scientists are finding treasure in our trash. Four recent papers published in ACS journals detail how food waste contains sustainable solutions for farming and new sources of bioactive compounds for pharmaceuticals. Reporters can request free access to these papers by emailing newsroom@acs.org.
Sugar by-product may “beet” wheat disease. Researchers report in ACS’ Journal of Agricultural and Food Chemistry that sugar beet pulp could help reduce agriculture’s reliance on synthetic pesticides. The pulp, about 80% of the beet’s ...
Shedding light on the impact of the Bank of Japan’s exchange-traded fund purchase program
2025-10-09
It is widely recognized that the Bank of Japan’s Exchange-Traded Fund (ETF) purchases had a substantial impact on stock prices. Market participants and media reports have often highlighted that the policy distorted market valuations. At the same time, they pointed out that ETF management appeared to accelerate stock lending activity as the number of ETFs held by the Bank of Japan increased over time. This pattern suggests that the stock market, particularly the lending market, has mechanisms that enhance market efficiency and counteract the effects of the Bank of Japan’s policy.
Recently, a team of researchers from Japan, led by Dr. Junnosuke ...
SeoulTech scientists develop AI-based patent abstract generator to discover and detail technology opportunities
2025-10-09
Patents are valuable for the generation of novel ideas through technology opportunity discovery. In recent years, scientists have made several attempts to identify technology opportunities by determining vacancies in patent maps—visual representations of patent distribution in particular technological fields created using dimensionality reduction techniques. However, there is a major bottleneck in this approach: it is challenging to precisely define and interpret the technological content of these patent vacancies.
In a breakthrough study, researchers from the Republic of Korea and the United States, led by Professor Hakyeon Lee of the Department ...
Scientists fix genetic defect in mice tied to brain disorders that include autism and epilepsy
2025-10-09
SEATTLE, WASH. — October 9, 2025 — In an exciting scientific first, researchers at the Allen Institute successfully designed a new gene therapy that reversed symptoms related to SYNGAP1-related disorders (SRD) in mice. These are a class of brain disorders that can lead to severe and debilitating symptoms including intellectual disability, epilepsy, motor problems, and risk-taking behaviors in humans. In most cases, SRDs are caused when someone has only one working copy of the SYNGAP1 gene instead of the normal ...
Body illusion helps unlock memories – new study
2025-10-09
New research has discovered that briefly altering how we perceive our own body can help unlock autobiographical memories – potentially even those from the early stages of childhood.
Published in the Nature journal Scientific Reports, the study is the first to find that adults can better access their early memories after embodying a childlike version of their own face.
Led by neuroscientists at Anglia Ruskin University (ARU) in Cambridge, the study of 50 adult participants involved an “enfacement illusion”, which allows people to experience a face they see on a computer screen as their own, as though looking in a mirror.
The participants ...
Hormone replacement therapy may help restore immunity in menopausal women
2025-10-09
A study led by researchers at Queen Mary University of London has found that hormone replacement therapy (HRT) may help reverse changes in the immune system caused by menopause, potentially booting immune health. The research reveals new evidence that menopause significantly alters women’s immune system, increasing their vulnerability to infections.
The study, published in Aging Cell is the first detailed analysis of how ageing and sex differences influence monocytes, a key group of immune cells that act as the body’s first responders to infection. Analysing blood samples from younger adults less than 40 years of age and older ...